February 17, 2022

Repertoire® Immune Medicines Enters Research Collaboration With UMass Chan Medical School to Identify the Underlying Immune Causes of Vitiligo

Read More

December 15, 2021

Repertoire Immune Medicines Appoints B. Lynne Parshall to Board of Directors

Read More

November 18, 2021

Repertoire Immune Medicines’ DECODE™ Platform Provided Comprehensive Characterization of CD8+ T Cell Responses to SARS-CoV-2 in New Research Published by Science Immunology

Read More

October 11, 2021

Repertoire Immune Medicines Announces First Patient Dosed in Phase 1 Clinical Study of RPTR-168 (PRIME IL-12) for Relapsed or Refractory HPV-16-Positive Tumors

Read More

June 7, 2021

Repertoire Immune Medicines to Present New Data From its DECODE™ Platform Program at FOCiS 2021

Read More

June 3, 2021

Anne Walker Joins Repertoire Immune Medicines as Executive Vice President and Chief Financial Officer

Read More

June 2, 2021

Repertoire Immune Medicines Announces Cell Publication Characterizing T Cell Response to Novel, Highly-Immunogenic SARS-CoV-2 Epitopes

Read More

May 26, 2021

Repertoire Immune Medicines Enters Collaboration to Advance Novel Antigen Discovery and T Cell Receptor Research in Melanoma

Read More

April 29, 2021

Repertoire Immune Medicines Enters Collaboration on Novel Antigen Discovery and T Cell Receptor Research in Multiple Sclerosis

Read More

April 27, 2021

Susan Hockfield, Ph.D., MIT President Emerita, Joins Repertoire Immune Medicines Board of Directors

Read More

April 13, 2021

Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets

Read More

April 9, 2021

Repertoire Immune Medicines to Present Data from Autologous T Cell Therapy -- PRIME IL-15 (RPTR-147) -- in Advanced or Metastatic Solid Tumor Cancers

Read More

March 16, 2021

Repertoire Immune Medicines to Present at Oppenheimer 31st Annual Healthcare Conference

Read More

March 3, 2021

Repertoire Immune Medicines Pre-publishes New Research Identifying Potential Mechanisms for Immune Escape of SARS-CoV-2 Variants to Support Novel Approaches for T Cell Based Therapeutic Development

Read More

February 12, 2021

Repertoire Immune Medicines Announces FDA Acceptance of IND for PRIME™ IL-12, an Autologous Multi-Targeted T Cell Candidate for HPV+ Solid Tumors

Read More

February 11, 2021

Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers

Read More

January 7, 2021

Repertoire Immune Medicines to Provide Progress Updates on Clinical Programs and Discovery Platform at J.P. Morgan Healthcare Conference

Read More

November 24, 2020

Repertoire Immune Medicines to Present at the 32nd Annual Piper Sandler Virtual Healthcare Conference

Read More

November 9, 2020

Repertoire Immune Medicines Presents First Clinical Data on PRIME IL-15 Cell Therapy in Advanced Metastatic Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read More

September 21, 2020

Repertoire Immune Medicines Names Anthony Coyle, Ph.D., President, Research and Development

Read More

August 31, 2020

Repertoire Immune Medicines to Present at the Citi 15th Annual BioPharma Virtual Conference

Read More

June 24, 2020

Repertoire Immune Medicines Receives Funding From COVID-19 High Performance Computing Consortium

Read More

April 23, 2020

Repertoire Immune Medicines Strengthens Executive Team; Names Biotech Industry Veterans to Key Roles

Read More

March 25, 2020

Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund

Read More

March 12, 2020

Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer

Read More